PitchSend

Investor Presentaiton

Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis submission schedule New Molecular Entities: Lead and supplementary indications LEAD INDICATIONS Appendix Innovation: Clinical trials References Abbreviations 2022 2023 2024 2025 ≥2026 ensovibep Lead SKO136 COVID19 iptacopan LNP023 PNH Lead JDQ443 JDQ443 Lead icenticaftor³ Lead 177 Lu-NeoB Lead iscalimab Lead QBW251 AAA603 CFZ533 MIJ821 Acute depression Lead 2/3L NSCLC (mono) COPD Multiple Solid Tumors Sjögren's syndrome sabatolimab Lead ligelizumab Lead branaplam Lead ianalumab Lead PPY9882 Lead MBG453 QGE031 LMI070 VAY736 Geographic atrophy HR-MDS Food allergy Huntington's disease Sjögren's syndrome remibrutinib Lead NIS793 Lead cipargamin Lead libvatrep Lead TNO155 Lead 1L Pancreatic cancer KAE609 SAF312 Solid tumors LOU064 Malaria severe COSP CSU UNR844 Presbyopia Lead pelacarsen Lead ganaplacide Lead LNA043 Lead TQJ230 KAF156 Knee osteoarthritis CVRR-Lp(a) Malaria uncomplicated YTB3231 Lead gevokizumab Lead LXE408 Lead 2L Diffuse large B-cell lymphoma VPM087 Visceral leishmaniasis 1st line CRC tislelizumab LCM Pluvicto LCM Pluvicto LCM Scemblix LCM cipargamin LCM ianalumab LCM Scemblix LCM AAA617 ABL001 KAE609 VAY736 ABL001 VDT482 AAA617 NEW INDICATIONS 1L Nasopharyngeal Carcinoma mCRPC, Pre-taxane MHSPC CML 1L Malaria uncomplicated SLE CML, 2L, pediatrics tislelizumab LCM iptacopan LCM tislelizumab LCM VDT482 LNP023 VDT482 NSCLC C3G 1L Small Cell Lung Cancer iptacopan LNP023 aHUS LCM JDQ443 LCM iscalimab LCM remibrutinib LCM JDQ443 CFZ533 LOU064 NSCLC (combo) Liver Tx Sjögren's syndrome iptacopan LCM remibrutinib LCM ianalumab LCM iptacopan LCM tislelizumab LCM LNP023 LOU064 VAY736 LNP023 VDT482 IgAN Multiple sclerosis АІН iMN Adj/Neo adj NSCLC tislelizumab LCM ianalumab LCM sabatolimab LCM tislelizumab LCM VAY736 MBG453 VDT482 VDT482 Unfit AML 1L Gastric Cancer Lupus Nephritis 1L Urothelial Cell Carcinoma tislelizumab LCM VDT482 1L ESCC tislelizumab LCM VDT482 Localized ESCC tislelizumab LCM VDT482 1L Hepatocellular Carcinoma 1. Development strategy being updated 2. Gyroscope acquisition 3. Out-licensing planned 43 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation